Patents by Inventor Guangmei Yan

Guangmei Yan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210228660
    Abstract: Use of a proteasome inhibitor and an alphavirus in the preparation of an anti-tumor medicament. The proteasome inhibitor can be used to prepare an alphavirus anti-tumor synergist. A pharmaceutical composition comprising a proteasome inhibitor and an alphavirus, including a pharmaceutical kit comprising the proteasome inhibitor and the alphavirus, and use of the proteasome inhibitor and the virus in the treatment of tumors, particularly tumors insensitive to the alphavirus.
    Type: Application
    Filed: May 22, 2019
    Publication date: July 29, 2021
    Inventors: Guangmei YAN, Haipeng ZHANG, Wenbo ZHU, Yuan LIN, Shoufang GONG, Jiankai LIANG, Jing CAI, Chunqiang LIU
  • Patent number: 10980850
    Abstract: Described herein is use of a Caspase activator and an oncolytic virus in the preparation of an anti-tumor drug. As described, Caspase activator can enhance the anti-tumor effect of oncolytic virus, and the combination of Caspase activator and oncolytic virus produces a significant synergistic anti-tumor effect, and demonstrates an effective therapy for the treatment of tumors that are less sensitive to other pharmaceutical treatments.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: April 20, 2021
    Assignee: Guangzhou Virotech Phamaceutical Co., Ltd.
    Inventors: Guangmei Yan, Jing Cai, Yuan Lin, Haipeng Zhang, Suizhen Lin, Shoufang Gong, Jun Hu, Xiao Xiao, Kai Li, Jiankai Liang, Yaqian Tan, Wenbo Zhu, Wei Yin
  • Publication number: 20210060035
    Abstract: Disclosed is a use of 5?-androstane-3?,5,6?-triol, an analogue, a deuterated derivative, and a pharmaceutically acceptable salt thereof in manufacture of a medicament for the treatment of hemorrhagic stroke in a patient. The hemorrhagic stroke is intracerebral hemorrhage or subarachnoid hemorrhage.
    Type: Application
    Filed: December 28, 2018
    Publication date: March 4, 2021
    Applicant: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTD
    Inventors: Guangmei YAN, Yijun HUANG, Wei YIN, Suizhen LIN
  • Publication number: 20200405793
    Abstract: Disclosed is the use of a mevalonate metabolic pathway inhibitor and an alphavirus in preparing an anti-tumor drug. The mevalonate metabolic pathway inhibitor can be used in preparing an alphavirus anti-tumor synergist. Disclosed are a pharmaceutical composition containing the mevalonate metabolic pathway inhibitor and the alphavirus, a drug kit containing the mevalonate metabolic pathway inhibitor and the alphavirus, and the use of the mevalonate metabolic pathway inhibitor and the alphavirus in treating tumors, especially those that are insensitive to the alphavirus.
    Type: Application
    Filed: December 28, 2018
    Publication date: December 31, 2020
    Inventors: Guangmei YAN, Jiankai LIANG, Wenbo ZHU, Haipeng ZHANG, Yuan LIN, Jing CAI, Shoufang GONG
  • Publication number: 20200392250
    Abstract: Provided are applications of a hexokinase 2-specific inhibitor in preparing a medicament for preventing and treating acute central nervous system injury.
    Type: Application
    Filed: February 6, 2018
    Publication date: December 17, 2020
    Applicant: Guangzhou Cellprotek Pharmaceutical Co., Ltd.
    Inventors: Guangmei YAN, Wei YIN, Yuan LI, Bingzheng LU, Longxiang SHENG
  • Patent number: 10835539
    Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: November 17, 2020
    Assignee: Guangzhou Cellprotek Pharmaceutical Co., Ltd.
    Inventors: Wei Yin, Jiesi Chen, Guangmei Yan, Bingzheng Lu, Wenbo Zhu, Haiyan Hu, Pengxin Qiu, Yijun Huang, Jingxia Zhang
  • Publication number: 20200330483
    Abstract: Disclosed is use of 5?-androst-3?,5,6?-triol or an analogue, a deuterated compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cerebral small vessel disease in a patient. The cerebral small vessel disease is preferably cerebral microbleed. The cerebral microbleed is spontaneous cerebral microbleed, drug-related cerebral microbleed, or traumatic cerebral microbleed. The present invention demonstrates that these compounds significantly enhance the clearance of extravascular hemoglobin, and thus can be used to treat cerebral small vessel disease.
    Type: Application
    Filed: December 28, 2018
    Publication date: October 22, 2020
    Applicant: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTD
    Inventors: Guangmei YAN, Wei YIN, Longxiang SHENG, Bingzheng LU, Yijun HUANG, Suizhen LIN
  • Publication number: 20200085892
    Abstract: Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.
    Type: Application
    Filed: November 12, 2019
    Publication date: March 19, 2020
    Applicant: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD
    Inventors: Guangmei YAN, Xiao XIAO, Jun HU, Kai LI, Jiankai LIANG, Yuan LIN, Haipeng ZHANG, Suizhen LIN
  • Patent number: 10517909
    Abstract: Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: December 31, 2019
    Assignee: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD
    Inventors: Guangmei Yan, Xiao Xiao, Jun Hu, Kai Li, Jiankai Liang, Yuan Lin, Haipeng Zhang, Suizhen Lin
  • Publication number: 20190262358
    Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.
    Type: Application
    Filed: March 25, 2019
    Publication date: August 29, 2019
    Inventors: Wei Yin, Jiesi Chen, Guangmei Yan, Bingzheng Lu, Wenbo Zhu, Haiyan Hu, Pengxin Qiu, Yijun Huang, Jingxia Zhang
  • Patent number: 10357500
    Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: July 23, 2019
    Assignee: Guangzhou Cellprotek Pharmaceutical Co., Ltd.
    Inventors: Wei Yin, Jiesi Chen, Guangmei Yan, Bingzheng Lu, Wenbo Zhu, Haiyan Hu, Pengxin Qiu, Yijun Huang, Jingxia Zhang
  • Publication number: 20190183948
    Abstract: This invention belongs to the field of biomedicine and relates to use of Bcl-xL inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that the Bcl-xL inhibitor can be used as an anti-tumor synergist for oncolytic virus. The present invention also relates to a pharmaceutical composition comprising Bcl-xL inhibitor and oncolytic virus, a pharmaceutical kit comprising Bcl-xL inhibitor and oncolytic virus, and use of Bcl-xL inhibitor and oncolytic virus for treating tumors, especially, tumors that are not sensitive to the oncolytic virus.
    Type: Application
    Filed: August 18, 2017
    Publication date: June 20, 2019
    Applicant: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD.
    Inventors: Guangmei YAN, Yaqian TAN, Yuan LIN, Haipeng ZHANG, Suizhen LIN, Shoufang GONG, Jun HU, Xiao XIAO, Kai LI, Jiankai LIANG, Jing CAI, Wenbo ZHU, Wei YIN
  • Publication number: 20190167737
    Abstract: Described herein is use of a Caspase activator and an oncolytic virus in the preparation of an anti-tumor drug. As described, Caspase activator can enhance the anti-tumor effect of oncolytic virus, and the combination of Caspase activator and oncolytic virus produces a significant synergistic anti-tumor effect, and demonstrates an effective therapy for the treatment of tumors that are less sensitive to other pharmaceutical treatments.
    Type: Application
    Filed: August 18, 2017
    Publication date: June 6, 2019
    Applicant: Guangzhou Virotech Pharmaceutical Co., Ltd.
    Inventors: Guangmei YAN, Jing CAI, Yuan LIN, Haipeng ZHANG, Suizhen LIN, Shoufang GONG, Jun HU, Xiao XIAO, Kai LI, Jiankai LIANG, Yaqian TAN, Wenbo ZHU, Wei YIN
  • Publication number: 20190167641
    Abstract: The present invention belongs to the field of biomedicine and relates to use of VCP (valosin-containing protein, VCP) inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that VCP inhibitor can be used in the preparation of an anti-tumor synergist for oncolytic virus. Meanwhile, the present invention relates to a pharmaceutical composition comprising VCP inhibitor and oncolytic virus, a pharmaceutical kit comprising VCP inhibitor and oncolytic virus, and use of VCP inhibitor and oncolytic virus for treating tumor, especially a tumor that is not sensitive to oncolytic virus. The present invention also relates to an anti-tumor administration system, characterized in that, comprising oncolytic virus and a reagent for detecting the expression level of VCP.
    Type: Application
    Filed: August 18, 2017
    Publication date: June 6, 2019
    Applicant: Guangzhou Virotech Pharmaceutical Co., Ltd.
    Inventors: Guangmei YAN, Haipeng ZHANG, Yuan LIN, Suizhen LIN, Jing CAI, Shoufang GONG, Jun HU, Xiao XIAO, Kai LI, Jiankai LIANG, Yaqian TAN, Wenbo ZHU, Wei YIN
  • Publication number: 20170304380
    Abstract: Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.
    Type: Application
    Filed: August 24, 2015
    Publication date: October 26, 2017
    Applicant: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD.
    Inventors: Guangmei YAN, Xiao XIAO, Jun HU, Kai LI, Jiankai LIANG, Yuan LIN, Haipeng ZHANG, Suizhen LIN
  • Publication number: 20170042909
    Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.
    Type: Application
    Filed: April 14, 2015
    Publication date: February 16, 2017
    Inventors: Wei Yin, Jiesi Chen, Guangmei Yan, Bingzheng Lu, Wenbo Zhu, Haiyan Hu, Pengxin Qiu, Yijun Huang, Jingxia Zhang
  • Patent number: 9320743
    Abstract: Disclosed is the use of 5?-androstane-3?,5,6?-triol in preparing neuroprotective drugs. The compound has significant protective effect against neuron injuries caused by cerebral ischemia, spinal cord ischemia or hypoxia and has no obvious toxic reaction within effective dose thereof.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: April 26, 2016
    Assignee: GUANGZHOU CELLPROTEK PHARMACEUTICAL LTD.
    Inventors: Guangmei Yan, Haiyan Hu, Tiandong Leng, Hanfei Sang, Jingxia Zhang, Pengxin Qiu, Shujia Zhou, Jiesi Chen, Xiuhua You
  • Publication number: 20160051685
    Abstract: A 5?-androstane-3?,5,6?-triol injection and its preparation are disclosed. The injection uses hydroxypropyl-?-cyclodextrin as a solubilizing agent and the active ingredient is present at a weight ratio of 1-20:40-500 to the hydroxypropyl-?-cyclodextrin. The injection may also comprise, by weight, 1-100 parts of at least one isotonic adjusting agent, 0-200 parts of at least one freeze drying filler, and 0-2000 parts of at least one solvent. The preparation method comprises dissolving hydroxypropyl-?-cyclodextrin solution, 5?-androstane-3?,5,6?-triol and at least one additional soluble excipient in water for injection in sequence to obtain a raw injection solution, and subjecting the raw injection solution to decolorization, depyrogenation, filtration and sterilization to obtain the injection. Drying the filtrate yields a solid for injection.
    Type: Application
    Filed: August 28, 2015
    Publication date: February 25, 2016
    Applicant: Guangzhou Cellprotek Pharmaceutical LTD.
    Inventors: Guangmei Yan, Haiyan HU, Jingxia ZHANG, Pengxin QIU, Ling LI, Ning TIAN
  • Patent number: 9265837
    Abstract: A 5?-androstane-3?,5,6?-triol injection and its preparation are disclosed. The injection uses hydroxypropyl-?-cyclodextrin as a solubilizing agent and the active ingredient is present at a weight ratio of 1-20:40-500 to the hydroxypropyl-?-cyclodextrin. The injection may also comprise, by weight, 1-100 parts of at least one isotonic adjusting agent, 0-200 parts of at least one freeze drying filler, and 0-2000 parts of at least one solvent. The preparation method comprises dissolving hydroxypropyl-?-cyclodextrin solution, 5?-androstane-3?,5,6?-triol and at least one additional soluble excipient in water for injection in sequence to obtain a raw injection solution, and subjecting the raw injection solution to decolorization, depyrogenation, filtration and sterilization to obtain the injection. Drying the filtrate yields a solid for injection.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: February 23, 2016
    Assignee: Guangzhou Cellprotek Pharmaceuticals Ltd.
    Inventors: Guangmei Yan, Haiyan Hu, Jingxia Zhang, Pengxin Qiu, Ling Li, Ning Tian
  • Patent number: 9161985
    Abstract: A 5?-androstane-3?,5,6?-triol injection and its preparation are disclosed. The injection uses hydroxypropyl-?-cyclodextrin as a solubilizing agent and the active ingredient is present at a weight ratio of 1-20:40-500 to the hydroxypropyl-?-cyclodextrin. The injection may also comprise, by weight, 1-100 parts of at least one isotonic adjusting agent, 0-200 parts of at least one freeze drying filler, and 0-2000 parts of at least one solvent. The preparation method comprises dissolving hydroxypropyl-?-cyclodextrin solution, 5?-androstane-3?,5,6?-triol and at least one additional soluble excipient in water for injection in sequence to obtain a raw injection solution, and subjecting the raw injection solution to decolorization, depyrogenation, filtration and sterilization to obtain the injection, Drying the filtrate yields a solid for injection.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: October 20, 2015
    Assignee: Guangzhou Cellprotek Pharmaceutical Ltd.
    Inventors: Guangmei Yan, Halyan Hu, Jingxia Zhang, Pengxin Qiu, Ling Li, Ning Tian